BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $30.00 price target on Verve Therapeutics (NASDAQ: VERV).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE